Q-omics provides the consensus-scored PRDM4 profile across patient tissues and cancer cell-line models. PRDM4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRDM4 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PRDM4 RNA expression shows 20,213 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where PRDM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM4 survival associations across molecular data types. PRDM4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM4 RNA expression–survival associations across cancer types. High PRDM4 expression shows unfavorable associations in MESO, CESC, LIHC and LUSC, but favorable associations in SCLC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PRDM4 RNA expression.
This table summarizes PRDM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRDM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM4 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, BRCA and CHOL. The HNSC box plot shows higher PRDM4 RNA expression in tumor versus normal tissue (log2 FC = +0.682, t-test p < 0.001).
This table shows molecular features associated with PRDM4 in patient tissues and cancer cell lines. In patient samples, PRDM4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
